The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting

Huazhong University of Science and Technology

Status and phase: Unknown; Phase 4

Conditions: General Anesthetic Drug Adverse Reaction; Coronary Artery Bypass Graft Redo

Treatments: Drug: propofol; Drug: sufentanil; Drug: Desflurane

Study type: Interventional

Funder types: Other

Identifiers

NCT02213718

20140627 (Other Identifier)

20140607

Details and patient eligibility

About

This study is to assess the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

Full description

Desflurane, one of the third-generation inhaled anesthetics, is introduced in clinical practice in 1990s. Decades of clinical use has provided evidence for desflurane's safe and efficacious use as a general anesthetic. Compared with other volatile anesthestics, it has several characteristics: lower blood and lipid solubility, more stable in vitro and the lowest in vivo metabolism. Its particular low fat solubility properties promote rapid equilibration and rapid elimination at the end of anesthesia which reduces slow compartment accumulation and promotes predictable emergence, early extubation, and the ability to rapidly transfer patients from the operating room to the recovery unit. In addition, several investigations found that patients with desflurane anesthesia recovered their protective airway reflexes and awakened to a degree sufficient to minimize the stay in the high dependency recovery area.

A burgeoning body of investigations has shown that desflurane can directly act on myocardial and vascular functions. Desflurane has coronary vasodilative effects in in situ canine hearts which is comparable to sevoflurane does. Although it is controversial regarding to the effect of desflurane on myocardial excitation-contraction coupling and electrophysiologic behavior, a elaborated study found desflurane induced a positive inotropic effect in rat myocardium in vitro compared with isoflurane. A recent study suggested that desflurane decreased right ventricular contractility much less and maintained the right over left pressures ratio at more favorable values compared with sevoflurane. Furthermore, substantial investigations found that clinically relevant concentration desflurane preconditioning or postconditioning could protect myocardium from ischemia-reperfusion in mammalian animal models or isolated human cardiac tissues. However, it is unclear whether desflurane can provide protection for patients with coronary artery disease. Therefore, this study is designed to investigate the effect of desflurane on myocardial function in patents who underwent coronary artery bypass grafting.

Enrollment: 60 estimated patients

Sex: All

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosed with CAD 2. ASAⅡ～Ⅲ

Exclusion criteria

1. Left ventricular ejection fraction <40%
2. Left ventricular aneurysm
3. Acute myocardial infarction in latest two weeks, atrial fibrillation
4. Associated vascular diseases, severe systemic diseases involving the renal and hepatic systems
5. Respiratory disease( forced vital capacity less than 50% of predicted values )
6. Preoperative left bundle branch block -

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Desflurane

Experimental group

Description:

desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)

Treatment:

Drug: Desflurane

Drug: sufentanil

propofol

Active Comparator group

Description:

intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).

Treatment:

Drug: sufentanil

Drug: propofol